Key result
Prothrombinase complex concentrate (activated or inactivated) appears to be the most effective option for reversing the effects of new oral anticoagulants based on hemostatic tests, though clinical efficacy data in bleeding patients is lacking.
Why the study?
Do reversal agents such as PCC and rFVIIa reverse the anticoagulant effects and improve hemostatic parameters in models of new oral anticoagulant use?
Systematic Review (n=23)
Do reversal agents such as PCC and rFVIIa reverse the anticoagulant effects and improve hemostatic parameters in models of new oral anticoagulant use?
The best available evidence suggests that PCC may be the most effective currently available option for reversing new oral anticoagulants, particularly rivaroxaban, though clinical efficacy data in bleeding patients is urgently needed.
Answers are grounded in this paper and cite their sources.
May guide PCC use for NOAC reversal on hemostatic tests alone; leaves open need for clinical outcome trials in bleeding patients.
New oral anticoagulants, including dabigatran, rivaroxaban, and apixaban, have been recently approved for primary and secondary prophylaxis of thromboembolic conditions. However, there is no clear strategy for managing and reversing their anticoagulant effects. We aimed to summarize the available evidence for clinical management and reversal of bleeding associated with new oral anticoagulants. Using a systematic review approach, we aimed to identify studies describing reversal strategies for dabigatran, rivaroxaban, and apixaban. The search was conducted using Medline, EMBASE, HealthSTAR, and grey literature. We included laboratory and human studies. We included 23 studies reported in 37 out of 106 potentially relevant references. Four studies were conducted in humans and the rest were in vitro and in vivo studies. The majority of the studies evaluated the use of prothrombinase complex concentrate (PCC), either activated or inactivated, and recombinant activated factor VII (rFVIIa). Other interventions were also identified. Laboratory studies suggest that hemostatic parameters and bleeding might be partially or completely corrected by PCC for rivaroxaban better than dabigatran. Studies in humans suggest that PCC might reverse the effects of rivaroxaban better than dabigatran assessed by hemostatic tests. We were not able to locate studies evaluating the clinical efficacy of these agents. The best available evidence suggests that PCC (activated or inactivated) might be the best option for reversing new anticoagulants. Evidence for rFVIIa is less compelling. There might be differences in the efficacy of reversing agents for different anticoagulants. Studies assessing the clinical efficacy of these reversal agents are urgently needed.
No takes yet. Share an insight, caveat, or question.
Lazo‐Langner et al. (2013) conducted a systematic review in Bleeding associated with new oral anticoagulants (n=23). Prothrombinase complex concentrate (PCC) and recombinant activated factor VII (rFVIIa) was evaluated on Reversal of anticoagulant effects assessed by hemostatic tests or bleeding models. Prothrombinase complex concentrate (activated or inactivated) appears to be the most effective option for reversing the effects of new oral anticoagulants based on hemostatic tests, though clinical efficacy data in bleeding patients is lacking.
Synapse has enriched 10 related papers. Consider them for comparative context: